Argentina's National Agency for the Promotion of Research, Technological Development and Innovation (Agencia I+D+i) granted funding worth AR$ 1.1 billion (around US$ 3.18 million at the unofficial exchange rate) to carry out clinical studies of phases II and III of the “ARVAC Cecilia Grierson” Covid 19 vaccine, it was reported.